Canadian drugmaker Tekmira says it has stopped enrolling new patients in a trial of a treatment for a strain of Ebola.
The company says the mid-stage study has "reached a predefined statistical endpoint" and it is no longer enrolling patients.
It hasn't described that statistical goal, but says adding new patients probably wouldn't have demonstrated a benefit for the drug.
Tekmira calls the drug TKM-Ebola-Guinea and it is designed to target the strain of the virus that is responsible for the active outbreak in West Africa.
More than 11,000 people have died since that outbreak began in December 2013.
The company has been studying the drug in Ebola patients in Sierra Leone.
Share
